<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01292746</url>
  </required_header>
  <id_info>
    <org_study_id>EC_FA001</org_study_id>
    <nct_id>NCT01292746</nct_id>
  </id_info>
  <brief_title>Study of the Effect of Low Level Laser Light on Hair Growth on the Female Human Scalp</brief_title>
  <official_title>An Evaluation of the Effect of the Erchonia ML Scanner (MLS) on the Treatment of Androgenic Alopecia in Females</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erchonia Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Erchonia Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical study is to determine if the Erchonia® ML Scanner (MLS) low&#xD;
      level laser light device can help to regrow hair on the scalp of females experiencing hair&#xD;
      loss or thinning.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Over 20 million women in the United States suffer from hair loss, and about 40% of those&#xD;
      women are under forty years of age. The emotional aspects of hair loss for females include&#xD;
      anxiety and depression, frustration and poor self-esteem. Androgenetic alopecia is a common&#xD;
      cause of female balding and the most likely reason for excessive hair loss.&#xD;
&#xD;
      It is believed that light therapy of the scalp will provide an effective means to reduce hair&#xD;
      loss and/or stimulate hair growth in females with androgenetic alopecia. Results of previous&#xD;
      studies on low level laser therapy (LLLT) have demonstrated a variety of in vitro and in vivo&#xD;
      effects including increased blood flow, accelerated wound healing, enhanced production of&#xD;
      cytokines and other cellular mediators, increased cellular proliferation, among a panoply of&#xD;
      other effects. Enhanced hair growth has been observed adjacent to treated areas in various&#xD;
      animal models investigating the effects of LLLT. Uncontrolled studies in humans and spa-based&#xD;
      therapies in Europe appear to show that the periodic application of low intensity light&#xD;
      therapy reduces hair loss and appears to increase hair growth. The majority of these&#xD;
      applications utilize light in the red and near-infrared portions of the spectrum.&#xD;
&#xD;
      The Erchonia MLS low level laser is being evaluated for its potential to improve the quality&#xD;
      and quantity of hair on the female scalp. This may improve the quality of life as a result of&#xD;
      improved self-image and may potentially delay or reduce the need for surgical procedures such&#xD;
      as hair transplantation. A successful local therapy would mitigate or reduce the need for&#xD;
      systemic agents such as minoxidil and finasteride, thereby minimizing the potential side&#xD;
      effects of these therapies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recruitment and subject study compliance was difficult&#xD;
  </why_stopped>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Non-vellus Terminal Hair Count Across a 3 cm Diameter Scalp Area</measure>
    <time_frame>Baseline and 13 Weeks</time_frame>
    <description>Non-vellus terminal hair count was calculated across a tattooed 3 cm diameter scalp area from digital photographs of the area by independent blinded evaluator employing macroimage analysis software.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Female Pattern Alopecia</condition>
  <arm_group>
    <arm_group_label>Erchonia ML Scanner (MLS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Erchonia MLS employs four diodes emitting 10 milliwatts (mW) 635 nanometer (nm) red laser light</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Erchonia MLS</intervention_name>
    <description>The Erchonia MLS administers 4 diodes of 10 milliwatts (mW) 635 nanometers (nm) red light to the scalp area for 18 minutes, 2 times each week for 12 consecutive weeks for a total of 24 treatments.</description>
    <arm_group_label>Erchonia ML Scanner (MLS)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female pattern androgenic alopecia defined as:&#xD;
&#xD;
               -  discernable decrease in hair density on the top of the scalp relative to the&#xD;
                  sides and back of the scalp (ii) classifications I-3, I-4, II-1, II-2 according&#xD;
                  to the Ludwig and Savin Hair Loss Scale&#xD;
&#xD;
          -  Notable hair loss/thinning onset within the past five years.&#xD;
&#xD;
          -  Progressive/active hair loss/thinning within the last 12 months.&#xD;
&#xD;
          -  Skin type I through IV according to the Fitzpatrick Skin Type Scale.&#xD;
&#xD;
          -  Healthy, balanced scalp, determined as one that shows no indication of notable:&#xD;
             dryness, flaking, dandruff (pityriasis), redness, irritation, inflammation, itching,&#xD;
             greasy/oily texture, odor, lesions, scalp acne or other significant dermatological&#xD;
             conditions.&#xD;
&#xD;
          -  PI or P2 on the American Society of Anesthesiologists (ASA) Physical Status&#xD;
             Classification System.&#xD;
&#xD;
          -  Willing and able to maintain same hair style, length, color and hair care regimen&#xD;
             throughout study participation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hair loss attributable to one or more of the following conditions: tinea capsitis,&#xD;
             secondary syphilis, discoid lupus erythematosus: Inflammation, alopecia areata,&#xD;
             trichotillomania, telogen effluvium, anagen effluvium, traumatic alopecia.&#xD;
&#xD;
          -  Use of any of the following medications presently or during the prior 6 months:&#xD;
             minoxidil, finasteride (or any other 5ᾳ-reductase inhibitor medications),medication&#xD;
             with anti-androgenic properties (e.g. cyproterone, spironolactone, ketoconazole,&#xD;
             flutamide and bicalutamide),topical estrogens, progesterone, tamoxifen, anabolic&#xD;
             steroids, medications that can potentially cause hypertrichosis (e.g. ciclosporin,&#xD;
             diazoxide, phenytoin and psoralens), oral glucocorticoids (inhaled glucocorticoids&#xD;
             permitted), lithium, phenothiazines.&#xD;
&#xD;
          -  Current use of other prescription and/or over-the-counter products known to affect&#xD;
             hair growth and distribution (e.g. saw palmetto, fish oil, corticosteroids,&#xD;
             antineoplastic agents, beta blockers, diazoxide, heparin, verapamil, warfarin, etc.).&#xD;
&#xD;
          -  Medical, physical, or other contraindications for, or sensitivity to, light therapy&#xD;
             (e.g. porphyria, photosensitizing drug therapies).&#xD;
&#xD;
          -  Taking Hormonal Replacement Therapy.&#xD;
&#xD;
          -  Conditions that may worsen with light therapy.&#xD;
&#xD;
          -  History of poor wound healing.&#xD;
&#xD;
          -  History of keloid formation.&#xD;
&#xD;
          -  Prior hair restoration/transplantation surgery.&#xD;
&#xD;
          -  Prior scalp reduction procedure(s).&#xD;
&#xD;
          -  Other surgery to the scalp region (e.g. to remove a skin cancer lesion).&#xD;
&#xD;
          -  Active skin infection, wound, or other external trauma to the scalp evaluation area.&#xD;
&#xD;
          -  Active malignancy or any malignancy in the past five years in the scalp evaluation&#xD;
             area.&#xD;
&#xD;
          -  Dermatological condition (dermatitis, eczema, psoriasis, etc.) of the scalp other than&#xD;
             female pattern hair loss.&#xD;
&#xD;
          -  Significant scarring (e.g. from burns) in the scalp evaluation area.&#xD;
&#xD;
          -  History of thyroid condition that may influence hair growth and loss.&#xD;
&#xD;
          -  Underlying medical condition(s) known to adversely affect hair growth or hair pattern,&#xD;
             such as HIV, connective tissue disease, inflammatory bowel disease.&#xD;
&#xD;
          -  Current hair weaves.&#xD;
&#xD;
          -  Use of non-breathable wigs.&#xD;
&#xD;
          -  Hairstyle is a &quot;buzz&quot; cut, defined as hair cut to less than one inch in length.&#xD;
&#xD;
          -  Tattooing of the scalp target evaluation area.&#xD;
&#xD;
          -  Subject is pregnant, nursing, planning a pregnancy, or less than six months&#xD;
             postpartum.&#xD;
&#xD;
          -  Serious mental health illness such as dementia or schizophrenia; psychiatric&#xD;
             hospitalization in the past two years.&#xD;
&#xD;
          -  Developmental disability or cognitive impairment that would preclude adequate&#xD;
             comprehension of the informed consent form and/or ability to record study&#xD;
             measurements.&#xD;
&#xD;
          -  Involvement in litigation/receiving disability benefits related in any way to the&#xD;
             parameters of the study.&#xD;
&#xD;
          -  Participation in research in the past 30 days.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul M Thaxton, MD, FACOG</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Advanced Gynecology Specialists of Georgia</name>
      <address>
        <city>Evans</city>
        <state>Georgia</state>
        <zip>30809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <study_first_submitted>February 8, 2011</study_first_submitted>
  <study_first_submitted_qc>February 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2011</study_first_posted>
  <results_first_submitted>July 9, 2015</results_first_submitted>
  <results_first_submitted_qc>November 7, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 11, 2015</results_first_posted>
  <last_update_submitted>November 7, 2015</last_update_submitted>
  <last_update_submitted_qc>November 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Erchonia MLS</title>
          <description>Erchonia MLS employs four diodes emitting 10 milliwatts (mW) 635 nanometer (nm) red laser light.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Erchonia MLS</title>
          <description>The Erchonia MLS administers 4 diodes of 10 milliwatts (mW) 635 nanometers (nm) red light to the scalp area for 18 minutes, 2 times each week for 12 consecutive weeks for a total of 24 treatments.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Non-Vellus Terminal Hair Count</title>
          <description>Non-vellus terminal hair count per centimeter squared (cm2) was calculated by independent evaluator analysis employing digital photograph images and macroimage analysis software</description>
          <units>hairs/cm2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="171.57" spread="60.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Non-vellus Terminal Hair Count Across a 3 cm Diameter Scalp Area</title>
        <description>Non-vellus terminal hair count was calculated across a tattooed 3 cm diameter scalp area from digital photographs of the area by independent blinded evaluator employing macroimage analysis software.</description>
        <time_frame>Baseline and 13 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Erchonia MLS</title>
            <description>Erchonia MLS: The Erchonia MLS administers 4 diodes of 10 milliwatts (mW) 635 nanometers (nm) red light to the scalp area for 18 minutes, 2 times each week for 12 consecutive weeks for a total of 24 treatments.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Non-vellus Terminal Hair Count Across a 3 cm Diameter Scalp Area</title>
          <description>Non-vellus terminal hair count was calculated across a tattooed 3 cm diameter scalp area from digital photographs of the area by independent blinded evaluator employing macroimage analysis software.</description>
          <units>hairs/cm2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.93" spread="13.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>2 sided t-test for correlated samples.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>13 Weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Erchonia MLS</title>
          <description>The Erchonia MLS administers 4 diodes of 10 milliwatts (mW) 635 nanometers (nm) red light to the scalp area for 18 minutes, 2 times each week for 12 consecutive weeks for a total of 24 treatments.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Consultant</name_or_title>
      <organization>Regulatory Insight, Inc.</organization>
      <phone>615-712-9743</phone>
      <email>elvira@reginsight.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

